Tag Archives: drug development

New Report Emphasizes the Role of Patent Protection in the Global Diffusion of New Drugs

medical_research

A new report from the National Bureau of Economic Research (NBER) has determined that strong patent protection accelerates the speed at which new drugs are launched in different countries. Providing affordable access is often challenged by the need to provide adequate incentives for developing new drugs, and ensuring affordable prices once they develop. Often neglected in the larger debate is that the speed at which drugs are launched and adopted in new countries is one Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Richard Pops: A Greater Patient Voice in Drug Development

ph-summit

In the October issue of MedNous, Alkermes’ CEO Richard Pops writes about the move toward increased engagement with patients in the development, review and delivery of new medicines, as well as the challenges and opportunities associated with access and reimbursement. Pops asserts that patients must organize to share data that can be used in regulatory decision-making. Furthermore, he writes that this input must be integrated through the process – from the early stages of development Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

WSJ Editorial: The Medical Innovation Threat

???????????????????????????????

An editorial in today’s Wall Street Journal looks at the rising threat the American insurance industry’s increasingly loud attacks on Sovaldi, a revolutionary new Hepatitis C treatment pose for medical innovation and the development of new specialty drugs. As the editors rightly note, “Sovaldi is the kind of medicine that the drug scolds claim to want—a true scientific advance with a near-perfect cure rate for Hepatitis C, the liver-destroying virus that infects one of every 100 Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

New York Times Building

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the attention the cost has received to date, those attacking the drug are “looking at the costs of Sovaldi in the wrong way.” Sanger-Katz acknowledges that these one-time treatments can be a ‘shock to the system,’ but notes the value far outweighs the expense since it cures the disease in the majority of patients, preventing further costly treatments and care. Sanger-Katz Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech Stocks: Perspective in a Bull Market

biotech companies

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,